A recent study in Nature Medicine shows semaglutide reduces kidney risks in non-diabetic obese patients with cardiovascular disease by 22%. The SELECT trial results highlight semaglutide's benefits for kidney function and overall cardiovascular health.
By Dr. Liji Thomas, MDMay 28 2024Reviewed by Benedette Cuffari, M.Sc. The use of semaglutide for non-diabetic obese patients with cardiovascular disease was first reported to be associated with significant benefit in the SELECT trial, where major adverse cardiovascular events were reduced by 20% in semaglutide recipients as compared to those on placebo. However, this trial was not analyzed for evidence of benefit for kidney function.
Some potential mechanisms involved in this association include an excessively high filtration rate, low-grade inflammation, focal segmental glomerulosclerosis, increased tubular reabsorption of sodium, which causes tubular damage and oxidative damage, and increased activity of the renin-angiotensin-aldosterone system, which causes vasoconstriction and increased blood pressure.
Related StoriesAbout 83% and 88% of semaglutide and placebo recipients completed the full treatment course, respectively. Data were available for nearly 97% of patients, and the status of surviving/death was known for almost all. Comparatively, patients with mildly low eGFR at baseline, which was defined as 60 mL/min/1.73/m2 or more, exhibited reduced eGFR during the study period with a difference of 0.57 mL/min/1.73/m2 favoring semaglutide recipients.
Semaglutide Albuminuria Blood Blood Pressure Body Mass Index Cardiovascular Disease Chronic Chronic Kidney Disease Creatinine Focal Segmental Glomerulosclerosis Glomerulosclerosis Inflammation Kidney Disease Kidney Failure Medicine Obesity Placebo
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Antrim 4-22 Carlow 2-22: Saffrons hold nerve to retain Leinster SHC berthAntrim will remain in the Leinster Senior Hurling Championship as they find the goal touch to overcome 14-man Carlow 4-22 to 2-22 in Belfast.
Read more »
Closed Loop Medicine and Pharmanovia commence OptiZest study for their first precision medicine combination therapeuticClosed Loop Medicine Ltd, a leading TechBio company developing combination prescription drug plus software therapy products that deliver personalized dose optimization, and Pharmanovia, a global pharmaceutical company that commercializes novel medicines and revitalizes, extends and expands the lifecycle of established medicines, today announced...
Read more »
Oral semaglutide shows promising results for type 2 diabetes in routine clinical settingsSemaglutide and its effects on glycemic control, body weight (BW), and tolerability in routine clinical practice.
Read more »
Semaglutide shows significant weight loss and health benefits in four-year obesity studyA study in Nature Medicine evaluated the effects of semaglutide on weight and anthropometric outcomes in adults with obesity but without diabetes, finding significant weight loss and improved health metrics over four years. The study also highlighted the safety and tolerability of semaglutide across different BMI categories.
Read more »
Taking semaglutide once weekly may lower the chances of kidney disease, says studyThe effects of semaglutide (administered once weekly) on the outcomes of kidney disease.
Read more »
Increased risk of erectile dysfunction with semaglutide in non-diabetic obese patientsResearchers found that semaglutide treatment for weight loss in non-diabetic, obese men is associated with an increased risk of erectile dysfunction and testosterone deficiency.
Read more »